From the Departments of Medical Oncology.
Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
Clin Nucl Med. 2021 Mar 1;46(3):e165-e167. doi: 10.1097/RLU.0000000000003382.
We offer an illustrative case about estrogen receptor (ER) imaging (also known as 16α-[18F]fluoro-17β-estradiol ([18F]-FES) PET) and the detection of metastatic lesions in the dural region. We present a case of a woman with ER-positive metastatic breast cancer and high [18F]-FES uptake in the dural region on PET imaging, without associated clinical symptoms. These lesions were missed on [18F]-FDG PET because of physiological [18F]-FDG uptake in the brain. This case highlighted some difficulties in the interpretation of imaging of brain metastases and demonstrated the added value of [18F]-FES PET imaging. [18F]-FES PET could be used to prove the presence of ER-positive metastases in the brain.
我们提供了一个关于雌激素受体（ER）成像（也称为 16α-[18F]氟-17β-雌二醇([18F]-FES) PET）和硬脑膜区域转移病灶检测的案例。我们介绍了一位 ER 阳性转移性乳腺癌女性的病例，其在 PET 成像中硬脑膜区域摄取高[18F]-FES，而无相关临床症状。由于大脑中生理性[18F]-FDG 摄取，这些病变在[18F]-FDG PET 上漏诊。该病例突出了脑转移成像解释的一些困难，并证明了[18F]-FES PET 成像的附加价值。[18F]-FES PET 可用于证明脑内存在 ER 阳性转移灶。
